RT Journal Article
SR Electronic
T1 The innate and adaptive immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20164848
DO 10.1101/2020.08.06.20164848
A1 Syrimi, Eleni
A1 Fennell, Eanna
A1 Richter, Alex
A1 Vrljicak, Pavle
A1 Stark, Richard
A1 Ott, Sascha
A1 Murray, Paul G
A1 Al-Abadi, Eslam
A1 Chikermane, Ashish
A1 Dawson, Pamela
A1 Hackett, Scott
A1 Jyothish, Deepthi
A1 Kanthimathinathan, Hari Krishnan
A1 Monaghan, Sean
A1 Nagakumar, Prasad
A1 Scholefield, Barnaby R
A1 Welch, Steven
A1 Khan, Naeem
A1 Faustini, Sian
A1 Kearns, Pamela
A1 Taylor, Graham S
YR 2021
UL http://medrxiv.org/content/early/2021/03/29/2020.08.06.20164848.abstract
AB Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MIS-C has overlapping clinical features with Kawasaki Disease (KD), a rare childhood vasculitis. MIS-C therapy is largely based on KD treatment protocols but whether these diseases share underpinning immunological perturbations is unknown. We performed deep immune profiling on blood samples from healthy children and patients with MIS-C or KD. Acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells; increased frequencies of B-cell plasmablasts and CD27-IgD-double-negative B-cells; and increased levels of pro-inflammatory (IL6, IL18, IP10, MCP1) but also anti-inflammatory (IL-10, IL1-RA, sTNFR1, sTNFR2) cytokines. Increased neutrophil count correlated with inflammation,cardiac dysfunction and disease severity. Two days after intravenous immunoglobulin (IVIG) treatment, MIS-C patients had increased CD163 expression on monocytes, expansion of a novel population of immature neutrophils, and decreased levels of pro- and anti-inflammatory cytokines in the blood accompanied by a transient increase in arginase in some patients. Our data show MIS-C and KD share substantial immunopathology and identify potential new mechanisms of action for IVIG, a widely used anti-inflammatory drug used to treat MIS-C, KD and other inflammatory diseases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical trial.All patient samples were obtained as part of a Health Research Authority approved study (TrICICL) reviewed and approved by South of Birmingham Research Ethics Committee (REC: 17/WM/0453, IRAS: 233593). Samples from seven healthy children (aged 12 years) were obtained via the Coronavirus Immunological Analysis study approved by North West - Preston Research Ethics Committee (REC: 20/NW/0240, IRAS: 282164). This study was performed in accordance with the declaration of Helsinki and written informed consent was obtained from all participants or their legal guardians.Funding StatementBirmingham Womens and Childrens Hospital Charity funded the single cell RNA sequencing analysis. ES is supported by a CRUK Birmingham Centre clinical PhD fellowship. BS is funded by a National Institute for Health Research (NIHR) Clinician Scientist fellowship.PGM is supported by the European Regional Development Fund (No. CZ.02.1.01/0.0/0.0/16_019/0000868)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patient samples were obtained as part of a Health Research Authority approved study (TrICICL) reviewed and approved by South of Birmingham Research Ethics Committee (REC: 17/WM/0453, IRAS: 233593). Samples from seven healthy children (aged 12 years) were obtained via the Coronavirus Immunological Analysis study approved by North West - Preston Research Ethics Committee (REC: 20/NW/0240, IRAS: 282164). This study was performed in accordance with the declaration of Helsinki and written informed consent was obtained from all participants or their legal guardians.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNAseq and mass data will be available upon article acceptance.